All lobbying filings

AVENUE SOLUTIONS

Lobbying for AMGEN, INC. · Biopharmaceutical company

Filing · LD-2 quarterly report Q2 report

Reporting period

2nd Quarter 2026

Apr 1 - June 30 · Posted Jul 20, 2026

Income

$50,000

What the client paid this registrant for the period.

Client based in

District of Columbia

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 1

Medicare/Medicaid

Issues related to drug pricing and reimbursement for prescription drugs; Issues related to H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to H.R. 5526/S. 1954, Biosimilar Red Tape Elimination Act; Issues related To S. 5459, The Biosimilar Access and Affordability Act; Issues related to Senate Finance Dear Colleague process

Bills named in this filing 4

H.R. 4299
Protecting Patient Access to Cancer and Complex Therapies Act
H.R. 5526
Biosimilar Red Tape Elimination Act
S. 1954
Biosimilar Red Tape Elimination Act
S. 5459
Biosimilars Access and Affordability Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.